ACTRIMS-ECTRIMS Meeting 2020
ACTRIMS-ECTRIMS Meeting 2020 provided health care professionals with an engaging lineup of scheduled and on-demand scientific multiple sclerosis content, along with a virtual exhibition and networking opportunities.
Understanding Costs of Infusion Disease-Modifying Drugs for Treatment of Multiple Sclerosis
“Costs associated with administering infusion DMDs among patients with MS in the US should be considered in economic analyses,” said researchers of a recent study.
Safety of Ofatumumab Remains Consistent for Relapsing MS Treatment
Researchers recently presented long-term data assessing the safety and benefit-risk profile of ofatumumab for the treatment of relapsing multiple sclerosis.
Examining Disease Modifying Therapy Utilization Rates in Patients With MS
“Since early initiation of disease modifying therapy has been associated with improved outcome [in MS patients], this phenomenon deserves further investigation,” explained researchers of a recent study.
